Eledon Pharmaceuticals (ELDN) stock

Transplant therapies , market cap $200M

Transplant therapies

Worth $200M

$2.76

-3.83%

As of Tuesday's close · Live for Pro members at the open

Why is ELDN down?

Down 3.8% today, more than its biotech peers' 1.4%; no story names it yet.

Ahead of the market

Up 150% over three years while the S&P 500 rose 80%.

Its filed figures weakened while the shares beat the market.

Sources: Price history, Nov 9, 2026; Quarterly reports, Jun 30, 2026

Tell me next time ELDN moves

Free account, no card. An optional alert when ELDN moves or its score changes.

Or see it live, free until Thursday morning. No account.

The other side, how the business stands, and the timeline, for Pro members.

Quality Score

-8

Poor

In its industry

#258of 281

Biotech

Checks firing

1of 14

Trending down

From 52-week high

-38.5%

under its best in a year

ELDN's Quality Score fell 2 points on Tue, Nov 10, to -8. It closed away from its high of the day (2 chart checks stopped).

Follow ELDN's trial news. Pro members can get an alert when Eledon Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ELDN files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextLate 2026“…of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026”Trial start · SEC filing · Aug 13

Cash$88.8M, about 4 quarters at the last year's spendingOn Jun 30 · the company says “into the second quarter of 2027”

Key facts on ELDN

Key facts on ELDN
Holding it back	47.3% more shares than a year ago
Latest filing	10-Q, Aug 13 Filed its quarterly report (10-Q) for the quarter to Jun 30, 2026

1 more reason behind ELDN's -8, free with an account →4 more reasons behind ELDN's -8, for Pro members.

ELDN in the news

TodayNo story names it yet.

Cash$88.8M, about 4 quarters at the last year's spendingOn Jun 30 · the company says “into the second quarter of 2027”

ELDN catalysts

Coming up

After its last 4 reports it closed -2.4% on average, higher 2 of 4 times.

What's next for ELDN, and how long its cash lasts

Next step the company has named

Late 2026“Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026”Trial start · SEC filing · Aug 13

What it means: when a trial begins, or reaches the stage the company named.

A trial underway: LEGACYPhase 3 · Not yet recruiting · 620 people · main data estimated Mar 2029 · NCT07835581

2 more trials, 1 more milestone and 28 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 4 quarters

$88.8M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into the second quarter of 2027” (8-K, Aug 13).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Sep 20, 2024)
At-the-market share sales program (S-3, filed Sep 20, 2024)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

Get an alert when David-Alexandre Gros buys or sells

For Pro members: every trade, and David-Alexandre Gros’s 3 filings and quotes.

Get an alert when ELDN files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why ELDN scores -8

Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means

-8 is below -5, off the left end of the scale.

−2Long-term trend below a falling 200-⁠day average, down over two years
−2Dilution 47.3% more shares outstanding than a year agoNew shares over the year: -1 at 10% more, -2 at 25% more.

Chart checks adds
Size subtracts
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Growth, Persistence, and News.

What every line is worth, and the reason behind it, on ELDN and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 10:45 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How ELDN ranks in Biotech

ELDN is #258 of 281 by Quality Score.

How ELDN ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	EDITEditas Medicine		Open for its score
	EIKNEikon Therapeutics		Open for its score
	ENTXEntera Bio		Open for its score
	EPRXEupraxia Pharmaceuticals		Open for its score
258	ELDNEledon Pharmaceuticals	1/14	-8

When does ELDN report earnings, and what happens after?

Expected to report Fri Nov 13, after the close (in 3 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

Close after the report, last 3

+1.1%+1.8%-4.3%

Mar 19May 13Aug 13

Reported	When	Gap	Reaction	5 days
Aug 13, 2026After close	After close	-2.7%	-4.3%	-4.9%
May 13, 2026After close	After close	+1.0%	+1.8%	-1.0%
Mar 19, 2026After close	After close	+0.7%	+1.1%	+3.9%

ELDN closed higher after 2 of its last 4 reports.

All 4 reports, and ELDN's Quality Score going into each

Everyone reporting earnings this week

ELDN has 1 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on ELDN, and all 14 on every stock.Get in free →

ELDN RSI today: 55.2, above its 50-day, below its 200-day

Not scored

RSI 55.2, MACD above signal, above its 50-day, below its 200-day. Not scored.13 readings

The deep dive on ELDN

What it does and how it makes money4 findings"We have licensed from UMB a U.S. patent covering a method of treating prostate cancer in a human subject by administering galeterone, which is expected to expire in 2027." (10-K for fiscal 2016)SEC filing · Mar 3, 2017
Where it stands1 finding1 offering of shares or notes since Nov 2025, $25.0M in all.SEC filing · Nov 13, 2025
What changed in its filings3 findings"On December 5, 2016, a putative securities class action was filed in the Business Litigation Session of the Superior Court Department of the Suffolk County Trial Court, Massachusetts ('Massachusetts State Court') against us, Jodie P." (10-Q for the quarter to Mar 31, 2017)SEC filing · May 3, 2017
Who holds and trades it1 findingFor Pro members1 finding on who holds and trades ELDN, for Pro members

6 more findings on ELDN, each with its source, for Pro members.

ELDN share count over time

47% more shares than a year earlier.

Weighted shares, quarter to Jun 30, 2026, both from one filing

Shares of ELDN outstanding, as filed
Shares outstanding	As of
81.3M	Aug 10, 2026
77.2M	May 7, 2026
75.9M	Mar 13, 2026
59.9M	Nov 7, 2025

Offerings, shelves, and splits of ELDN, from its filings
From its filings	Filed
Registered shares for a later sale (S-3)	May 1, 2026
Raised $25M in a sale of shares, about 13% of its market value	Nov 13, 2025
Priced a sale of shares	Oct 30, 2024
Registered shares for a later sale (S-3)	Sep 20, 2024

ELDN's officers and directors

Officers and directors with a Form 4 in the last 12 months.

David-Alexandre C. GrosChief Executive Officer · no trades on file
Steven PerrinPresident · no trades on file
Allan KirkDirector · no trades on file
James A. Robinson Jr.Director · no trades on file
Jan HillsonDirector · no trades on file
John S. McBrideDirector · no trades on file
June LeeDirector · no trades on file
Keith KatkinDirector · no trades on file

See insider trades by person

Which ETFs hold ELDN?

In ETFs: ELDN is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.

33 employeesIrvine, CAeledon.com

What Eledon Pharmaceuticals says it competes with

“The development and commercialization of new drug products is highly competitive.”

From its annual report, SEC filing · Mar 3, 2017

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on ELDN and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn ELDN's score around: 8 things
6 more filings explained, a plain line each
Real-⁠time prices, no delay

See ELDN's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: ELDN's Quality Score is -8 (Poor), #258 of 281 in Biotech.

What does ELDN's Quality Score say?

ELDN scores -8 today, which Breakaway calls Poor. It is #258 of 281 in Biotech by Quality Score, with 1 of 14 chart checks firing. Up 150% over three years while the S&P 500 rose 80%. Cash lasts about 4 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ELDN's Quality Score?

ELDN scores -8 today, which Breakaway calls Poor (below zero). That is #258 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ELDN's -8.

When does ELDN report earnings?

Expected to report Fri Nov 13, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. ELDN closed higher after 2 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.